Skip to main content
Signal8

Trombley Aetna Wun

SEC insider (Form 3/4/5 filer). CIK 0001750495. President and CEO at Lycia Therapeutics, Inc. (LYCA). 1 reported Form 4/5 transaction since Sep 2024; latest on Aug 11, 2026. Located in SOUTH SAN FRANCISCO, CA.

Companies Trombley Aetna Wun has filed insider reports for

  • Lycia Therapeutics, Inc. (LYCA): Director, Officer, 10% Owner, President and CEO
Trombley Aetna Wun profile photo

Trombley Aetna Wun

CIK: 0001750495

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Lycia Therapeutics, Inc. logo
LYCA

Lycia Therapeutics, Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (1 total)

  • Lycia Therapeutics, Inc. logo
    LYCA

    Lycia Therapeutics, Inc.

    Aug 11, 2026
    Award

    Stock Option (Right to Buy)

    Direct
    443.6K shares-

1-1 of 1